Asthma Control clinical trials

Explore recruiting asthma control clinical trials.

Recruiting asthma control studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Asthma Control trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

Poland, France, Slovakia, Spain, Hungary, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

Germany, Spain, Poland, Hungary, Czechia, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma. DRI17509

Italy, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for Tezepelumab-treated Patients with Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission (ARRIVAL)

Germany, Bulgaria, Denmark, Spain, France, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy

Czechia, Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Asthma Control trials by city

Asthma Control in Toronto Asthma Control in Vancouver Asthma Control in Montreal Asthma Control in Calgary Asthma Control in Edmonton Asthma Control in Ottawa Asthma Control in Winnipeg Asthma Control in Quebec City Asthma Control in Hamilton Asthma Control in Kitchener Asthma Control in London Asthma Control in Halifax Asthma Control in New York Asthma Control in Los Angeles Asthma Control in Chicago Asthma Control in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease